Anandamide and R- (+) -methanandamide prevent development of ischemic and reperfusion arrhythmia in rats by stimulation of CB2-receptors
Krylatov, A.V.; Uzhachenko, R.V.; Maslov, L.N.; Ugdyzhekova, D.S.; Bernatskaia, N.A.; Pertwee, R.; Stefano, G.B.; Makriyannis, A.
Eksperimental'naia i Klinicheskaia Farmakologiia 65(3): 6-9
2002
ISSN/ISBN: 0869-2092 PMID: 12227101 Document Number: 544132
It has been found that prior intravenous administration of the endocannabinoid anandamide (10 mg/kg) or its synthetic analogue R-(+)-methanadamide (5 mg/kg) prevents a development of ischemic and reperfusion arrhythmias in rats. The prior injection of the CB1 receptor antagonist, SR 141716A (3 mg/kg), did no affect the antiarrhythmic action of both cannabinoids. Pretreatment with the CB2 receptor antagonist, SR 144528 (1 mg/kg), completely abolished antiarrhythmic effect of anandamide and R-(+)-methanandamide. Both CB antagonist had no effect on the arrhythmias itself. Pretreatment with the NO-synthase inhibitor, L-NAME (50 mg/kg), had no effect on the antiarrhythmic action of cannabinoids. We therefore conclude that CB2 receptor stimulation increases the heart tolerance to ischemic and reperfusion arrhythmias.